Document is current
Any future updates will be listed below
-
Authors
Gupta, Avantika https://orcid.org/0000-0002-8170-6720
Gazzo, Andrea
Selenica, Pier
Safonov, Anton
Pareja, Fresia https://orcid.org/0000-0003-3748-8049
da Silva, Edaise M. https://orcid.org/0000-0003-3281-7333
Brown, David N. https://orcid.org/0000-0002-8249-3632
Shao, Hong
Zhu, Yingjie https://orcid.org/0000-0003-1849-6019
Patel, Juber
Blanco-Heredia, Juan https://orcid.org/0000-0001-9526-7450
Stefanovska, Bojana https://orcid.org/0000-0003-2212-8200
Carpenter, Michael A. https://orcid.org/0000-0001-9524-5323
Chen, Yanjun
Vegas, Isabella https://orcid.org/0009-0005-2437-7130
Pei, Xin https://orcid.org/0000-0001-9961-6152
Frosina, Denise
Jungbluth, Achim A.
Ladanyi, Marc https://orcid.org/0000-0001-9055-7213
Curigliano, Giuseppe https://orcid.org/0000-0003-1781-2518
Weigelt, Britta https://orcid.org/0000-0001-9927-1270
Riaz, Nadeem https://orcid.org/0000-0001-9873-5862
Powell, Simon N. https://orcid.org/0000-0002-8183-4765
Razavi, Pedram https://orcid.org/0000-0003-4236-0576
Harris, Reuben S. https://orcid.org/0000-0002-9034-9112
Reis-Filho, Jorge S.
Marra, Antonio https://orcid.org/0000-0002-7310-7824
Chandarlapaty, Sarat https://orcid.org/0000-0003-4532-8053
-
Funding
Funding for this research was provided by:
Breast Cancer Research Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50 CA247749, P30 CA008748, P50 CA24779, P50 CA247749 01, P50-CA247749, P01-CA234228, P50 CA247749 01)
Naddisy Foundation, Cancer Couch Foundation
Starr Cancer Consortium
Cycle for survival
Recruitment of Established Investigators Award from the Cancer Prevention and Research Institute of Texas
Susan G. Komen
- License Information
-
More Information
Article History
Received: 8 May 2024
Accepted: 1 April 2025
First Online: 16 May 2025
Competing interests
: S.C. has received institutional grant/funding from Daiichi Sankyo, AstraZeneca, and Lilly, Shares/Ownership interests in Totus Medicines and consultation/Ad board/Honoraria from AstraZeneca, Lilly, Daiichi Sankyo, Novartis, Neogenomics, Nuvalent, Blueprint, SAGA Diagnostics and Effector Therapeutics. J.S.R.-F. is employed by AstraZeneca and reports receiving personal/consultancy fees from Goldman Sachs, Bain Capital, REPARE Therapeutics, Saga Diagnostics and Paige.AI, membership of the scientific advisory boards of VolitionRx, REPARE Therapeutics and Paige.AI, membership of the Board of Directors of Grupo Oncoclinicas and ad hoc membership of the scientific advisory boards of AstraZeneca, Merck, Daiichi Sankyo, Roche Tissue Diagnostics and Personalis, outside the submitted work. P.R. has received institutional grant/funding from Grail, Novartis, AstraZeneca, Epic Sciences, Invitae/ArcherDx, Biothernostics, Tempus, Neogenomics, Biovica, Guardant, Personalis and Myriad, Shares/Ownership interests in Odyssey Biosciences and consultation/Ad board/Honoraria from Novartis, AstraZeneca, Pfizer, Lilly/Loxo, Prelude Therapeutics, Epic Sciences, Daiichi Sankyo, Foundation Medicine, Inivata, Natera, Tempus, SAGA Diagnostics, Paige.AI, Guardant and Myriad. S.N.P. has received funding for research from AstraZeneca, Philips and Varian, and reports consulting activity for Repare Therapeutics and AstraZeneca. N.R. has received research funding from BMS, Pfizer and REPARE therapeutics. B.W. reports research funding from Repare Therapeutics, outside the submitted work. F.P. is a member of the scientific advisory board of MultiplexDx. In addition, F.P. serves on the diagnostic advisory board and reports receiving consultancy fees from AstraZeneca. A. Gazzo reports consulting activity at enGenome and Janssen. The other authors declare no competing interests.
